I Ranked 12 Fat-Loss Peptides: What Actually Works, What’s Overhyped, and What the Science Says

The fat-loss game has changed. And if you're still approaching weight loss the same way people did ten or fifteen years ago, you're probably missing some of the most interesting developments in metabolic research.

For years, the formula was simple: eat less, train harder, burn more calories. Energy balance still matters, but hormones, appetite signaling, metabolic pathways, and cellular processes make the real picture far more complicated.

I'm Nicholas Trigili, a former IFBB professional bodybuilder and performance coach. I've spent years studying performance, physique development, and strategies for changing body composition. I've personally experimented with compounds discussed in the peptide community.

Not every compound receiving attention deserves it. Some have substantial human research behind them; others have exciting biological theories but little clinical evidence. I originally ranked twelve compounds from S-tier to F-tier. Those rankings reflect my personal, bodybuilding-oriented opinion, not clinical guidance.

1. Semaglutide: Why I Put a Proven Medication in F-Tier

Let's start with a controversial placement: semaglutide, the active ingredient in Ozempic and Wegovy. I originally put it in F-tier. That doesn't mean it fails to work. Semaglutide has substantial clinical evidence supporting weight reduction in appropriate patients.

It activates GLP-1 receptors, helps regulate appetite and fullness, and slows gastric emptying. My criticism was comparative: other medications have produced greater average weight reduction in some studies. A medicine can be highly useful without ranking first for magnitude of weight loss.

I also pay close attention to muscle preservation. Significant weight loss can include loss of lean mass, regardless of the medication. Nutrition, adequate protein, resistance exercise, and clinical monitoring matter. My F-tier grade is subjective and does not negate semaglutide's established indications.

2. Tirzepatide: Two Hormone Signals Instead of One

Tirzepatide, known as Mounjaro and Zepbound, acts at both GLP-1 and GIP receptors. Those pathways work together in glucose regulation, appetite control, and metabolic signaling.

The dual-receptor design can produce substantial weight loss. It isn't free of trade-offs: gastrointestinal adverse effects occur, tolerability varies, and lean mass may decline alongside fat during major weight reduction.

My original ranking was B-tier. I regard it as a major development in obesity medicine, but body composition and longer-term treatment decisions matter as much as scale weight.

3. Retatrutide: The Triple-Action Compound

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. That's why I find it so interesting. It combines signals relating to appetite, nutrient regulation, and the handling of stored fuel.

Clinical studies have reported substantial reductions in body weight, generating attention across metabolic research. But an investigational drug is not the same as a proven, approved treatment for general use, and trial averages cannot predict an individual person's experience.

I originally ranked retatrutide S-tier and discussed my own experimentation with it. That description is personal experience, not a recommended dosing protocol. Safety, eligibility, and regulatory evaluation remain essential.

4. Tesamorelin: Why Visceral Fat Matters

Growth hormone signaling represents a very different pathway. Tesamorelin, a growth hormone-releasing hormone analog, stimulates endogenous growth hormone release.

Excess visceral fat accumulates deep inside the abdomen. Tesamorelin has an FDA-approved indication related to excess abdominal fat in adults with HIV-associated lipodystrophy. That specific indication should not be confused with approval for general cosmetic abdominal-fat reduction or obesity treatment. I originally placed it in S-tier for its targeted research history. It also carries meaningful risks, including changes in glucose regulation, IGF-1 elevation, and fluid retention.

5 and 6. CJC-1295 and Ipamorelin

These compounds are often mentioned together because they act on different pathways involved in growth hormone signaling. CJC-1295 is related to growth hormone-releasing hormone activity; ipamorelin acts through the growth hormone secretagogue receptor.

That complementary biology sounds compelling, and it's why I placed both in A-tier. But theoretical signaling synergy does not establish better fat loss, sleep, muscle retention, or recovery in healthy adults. Human clinical evidence is insufficient to establish the safety or effectiveness of this combination for general performance or physique enhancement.

7. AOD-9604: A Fat-Burning Fragment With a Complicated History

AOD-9604 is a synthetic fragment associated with human growth hormone research. Scientists investigated whether effects on fat metabolism might be separated from broader growth hormone actions.

The mechanism generated interest, but clinical development did not establish AOD-9604 as an effective standard obesity treatment. Laboratory findings about lipolysis should not be confused with reliable human weight-loss outcomes.

My original B-tier ranking reflected interest in the concept more than evidence of strong standalone results.

8. MOTS-c: Why Mitochondrial Research Fascinates Me

Mitochondria are crucial to cellular energy production. MOTS-c, encoded within mitochondrial DNA, has attracted attention for potential roles in cellular stress responses and metabolic regulation. Preclinical work suggests possible influences on glucose metabolism and exercise-related adaptation. Still, calling it 'exercise in a vial' oversimplifies a process involving muscles, the cardiovascular system, the nervous system, and much more.

I ranked MOTS-c A-tier for scientific interest. There is inadequate human clinical evidence that injected MOTS-c reliably increases endurance, boosts metabolism, or speeds fat loss.

9. SS-31: Mitochondrial Protection From Another Angle

SS-31, also known as elamipretide, has been studied for interactions with the mitochondrial inner membrane and cardiolipin, an important mitochondrial lipid.

Specific mitochondrial disease research is different from general-purpose fat-loss claims. Even evidence in a defined clinical indication cannot automatically be extended to healthy people seeking improved physique or performance.

My A-tier placement recognized the importance of mitochondrial research, not proof that combining SS-31 with MOTS-c improves weight reduction.

10. SLU-PP-332: An Exercise-Mimicking Research Molecule

SLU-PP-332 is an experimental small molecule, not technically a peptide. It activates estrogen-related receptors involved in some energy-metabolism and mitochondrial pathways.

Animal studies have generated interest in exercise-like metabolic responses, but robust human evidence and validated dosing or safety standards are lacking.

I assigned B-tier as a speculative research ranking, not as a recommendation for human use.

11. 5-Amino-1MQ: A Different Metabolic Target

5-Amino-1MQ is another small molecule rather than a peptide. It targets nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide metabolism and other pathways. Interest in its effects on experimental metabolic models should not be mistaken for demonstrated weight-loss efficacy in people. In my original discussion, I acknowledged that I had not seen especially impressive standalone results.

I ranked it B-tier because of its research concept, while recognizing the limitations of current human evidence and safety data.

12. Melanotan II: Why the Risks Change My Ranking

Melanotan II is usually discussed as a tanning compound, but its actions at multiple melanocortin receptors also explain why appetite comes up in discussions.

It can cause nausea, flushing, pigmentation changes, sexual effects, and changes in moles. Concerns surrounding abnormal pigmented lesions demand caution, even though the evidence does not establish that it necessarily causes melanoma.

I placed it in F-tier. For fat loss, the lack of validated clinical benefit and its risks make it particularly hard to justify.

My Complete Ranking

These are the speaker’s subjective rankings from the original discussion. They are not comparative clinical-evidence or safety grades. In particular, semaglutide and tirzepatide have much stronger human obesity-treatment evidence than most experimental compounds listed here.

S-tier: Retatrutide, Tesamorelin.

A-tier: CJC-1295, Ipamorelin, MOTS-c, SS-31.

B-tier: Tirzepatide, AOD-9604, SLU-PP-332, 5-Amino-1MQ.

F-tier: Semaglutide, Melanotan II.

Why I Became Interested in Combining Different Mechanisms

In bodybuilding circles, a stack means combining substances for one desired outcome. The logic sounds simple: one agent influences appetite, another growth hormone, another mitochondrial function. But different mechanisms do not automatically mean proven synergy.

My original video described a hypothetical 90-day physique scenario involving retatrutide, MOTS-c, SS-31, growth hormone secretagogues, and tesamorelin. That scenario is not a validated clinical protocol. There are no adequate controlled trials showing that combining these experimental compounds is safe or superior to established approaches.

What I still think is useful is understanding how many systems influence body composition: appetite, energy expenditure, hormonal signaling, training adaptation, and muscle preservation.

The Muscle-Loss Problem Nobody Should Ignore

I've spent years building muscle and know how hard it is to preserve. When somebody loses twenty or thirty kilograms, I want to know how much was fat, how much was lean tissue, and what happened to their strength and functional capacity.

Resistance training, sufficient nutrition and protein, appropriate medical oversight, and sustainable weight management matter. Often, these fundamentals do more to preserve health and performance than adding another experimental compound.

Why I Believe the Future of Fat Loss Is More Than Appetite Suppression

Across these twelve substances, I see several different research directions: incretin medicines transforming obesity treatment, hormone-related therapies with specific indications, and experimental efforts to understand mitochondria and cellular metabolism.

The exciting part is how much scientists are discovering about the physiology of body weight. But that doesn't mean every molecule should be used, or that mixing unapproved products accelerates results safely.

My Final Takeaway: Don’t Confuse More Compounds With Better Results

There isn't one magic pathway that controls body fat. Appetite matters. Metabolic regulation matters. Energy balance matters. And preserving muscle matters.

Some compounds on my original list have strong clinical evidence. Others remain preclinical or investigational, and two are not technically peptides at all. My tiers reflect a personal perspective, not a substitute for medical evaluation.

If you're interested in any treatment, ask what it actually does, whether benefits have been demonstrated in humans, what risks it carries, and whether the evidence supports your goal. Getting leaner is one goal. Getting leaner while remaining healthy, strong, and capable is the goal that really matters.